Sarcoidosis following alemtuzumab treatment for multiple sclerosis

被引：25

作者：

Willis, Mark D. ^{[1
,2
,3
]}

Hope-Gill, Ben ^{[4
]}

Flood-Page, Patrick ^{[5
]}

Joseph, Fady ^{[6
]}

Needham, Ed ^{[7
]}

Jones, Joanne ^{[7
]}

Coles, Alasdair ^{[7
]}

Robertson, Neil P. ^{[1
,2
,3
]}

机构：

[1] Cardiff Univ, Inst Psychol Med & Clin Neurosci, Heath Pk, Cardiff CF14 4XN, S Glam, Wales

[2] Univ Hosp Wales, Heath Pk, Cardiff CF14 4XN, S Glam, Wales

[3] Univ Hosp Wales, Dept Neurol, Cardiff, S Glam, Wales

[4] Univ Hosp Llandough, Dept Resp Med, Llandough, Wales

[5] Royal Gwent Hosp, Dept Resp Med, Newport, Gwent, Wales

[6] Royal Gwent Hosp, Dept Neurol, Newport, Gwent, Wales

[7] Addenbrookes Hosp, Dept Neurol, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷 / 13期

关键词：

Multiple sclerosis; alemtuzumab; IMMUNE RECONSTITUTION;

D O I：

10.1177/1352458518790391

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date, these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report three (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.

引用

页码：1779 / 1782

页数：4

共 50 条

[1] SARCOIDOSIS FOLLOWING ALEMTUZUMAB TREATMENT FOR MULTIPLE SCLEROSIS
Willis, M. D.
May, K.
Hope-Gill, B.
Flood-Page, P.
Jeffrey, D.
Joseph, F.
Robertson, N. P.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A54 - A55
[2] Melanoma following treatment with alemtuzumab for multiple sclerosis
Pace, A. A.
Zajicek, J. P.
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (04) : E70 - E71
[3] Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment
Graf, Jonas
Ringelstein, Marius
Lepka, Klaudia
Schaller, Joerg
Quack, Helmut
Hartung, Hans-Peter
Aktas, Orhan
Albrecht, Philipp
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (13) : 1776 - 1778
[4] Cardiac sarcoidosis requiring ICD placement and immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis
Erlich-Malona, Natalie
Cahill, Jonathan
Chaudhry, Saima
Martin, Janice
Rizvi, Syed
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 47
[5] HYPERSENSITIVITY PNEUMONITIS FOLLOWING ALEMTUZUMAB TREATMENT FOR MULTIPLE SCLEROSIS
Willis, Mark
Cossburn, Mark
Ingram, Gillian
Pickersgill, Trevor
Barry, Simon
Robertson, Neil
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11):
[6] Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis
Giarola, Blake
Massey, Jennifer
Barnett, Yael
Rodrigues, Michael
Sutton, Ian
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 28 : 31 - 33
[7] Predicting Autoimmunity Following Treatment of Multiple Sclerosis with Alemtuzumab
Jones, Joanne
Compston, Alastair
Coles, Alasdair
CLINICAL IMMUNOLOGY, 2010, 135 : S103 - S103
[8] Predicting autoimmunity following treatment of multiple sclerosis with alemtuzumab
Jones, J. L.
Compston, D. A. S.
Coles, A. J.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S459 - S459
[9] Anemia and sarcoidosis following treatment with alemtuzumab
Love, Brandy
McCombe, Jennifer A.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
[10] TUMEFACTIVE DEMYELINATION FOLLOWING TREATMENT FOR RELAPSING MULTIPLE SCLEROSIS WITH ALEMTUZUMAB
Barton, Joshua
Hardy, Todd A.
Riminton, Sean
Reddel, Stephen W.
Barnett, Yael
Coles, Alasdair
Barnett, Michael H.
NEUROLOGY, 2017, 88 (10) : 1004 - 1006

← 1 2 3 4 5 →